LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Strona główna・Stock List・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Closed

SectorHealthcare

46.81 0.32

Buy Sell

Overview

Share price change

24h

Current

Min

46.49

Max

47.72

Key metrics
By Trading Economics
Income	882M 2.2B
Sales	-47M 12B
P/E Sector Avg	15.913 105.69
EPS	1.46
Dividend yield	5.31
Profit margin	17.959
Employees	34,100
EBITDA	820M 4.1B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+12.52% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	5.31% 2.37%

Market Stats
By TradingEconomics
Market Cap	7B 96B
Previous open	46.49
Previous close	46.81

News Sentiment

By Acuity

35%

65%

127 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

N/A / 50.57 Support & Resistance

Bristol-Myers Squibb Co. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 paź 2025, 11:14 UTC

Earnings

Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance

10 paź 2025, 12:32 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion

31 lip 2025, 11:14 UTC

Earnings

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

6 lis 2025, 20:02 UTC

Acquisitions, Mergers, Takeovers

Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments. -- Barrons.com

30 paź 2025, 16:52 UTC

Acquisitions, Mergers, Takeovers

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- WSJ

30 paź 2025, 16:52 UTC

Acquisitions, Mergers, Takeovers

Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ

30 paź 2025, 11:32 UTC

Earnings

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis, Which Was More Than Offset by Expected Continued Generic Impact Across Remainder of Legacy Portfolio >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of 80c Loss Per Shr Net Impact Related to Acquired IPRD Charges and Licensing Income >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 3Q Adjusted Gross Margin 72.9% >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B Vs Prior Outlook $46.5B-$47.5B >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Raised 2025 Rev Guidance Primarily Reflects Continued Strong Performance of Growth Portfolio >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: 3Q Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Reblozyl, Camzyos and Breyanzi >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12% to $5.37B >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb Adjusts 2025 View To Adj EPS $6.40-Adj EPS $6.60 Vs Prior Outlook $6.35-$6.65 >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 3Q Gross Margin 71.9% >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Latest 3Q Includes Net Impact of Loss of 20c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 3Q Adj EPS $1.63 >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 3Q Rev $12.22B >BMY

30 paź 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 3Q EPS $1.08 >BMY

10 paź 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10 paź 2025, 11:02 UTC

Acquisitions, Mergers, Takeovers

Bristol-Myers Squibb to Pay $1.5B in Cash at Closing to Acquire Orbital >BMY

10 paź 2025, 11:01 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics

4 sie 2025, 11:59 UTC

Earnings

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

31 lip 2025, 11:54 UTC

Earnings

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

12.52% upside

12 Months Forecast

Average 52.67 USD 12.52%

High 68 USD

Low 36 USD

Based on 18 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to Bristol-Myers Squibb Co. - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 50.57Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

127 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.